Research Article

Primary Cutaneous Lymphomas and Interferon Treatment

Ajda ERSOY GUNES, Melda COMERT OZKAN*, Fahri SAHIN and Guray SAYDAM

Published: 01/09/2017 | Volume 1 - Issue 1 | Pages: 001-010

ABSTRACT

Primary cutaneous lymphomas (PCLs) are the second most common group of extranodal non-Hodgkin lymphomas (NHL) with an estimated annual incidence of 1/100.000. Interferons (IFNs) are used in mono or combination therapy for cutaneous lymphomas especially for cutaneous T-cell lymphomas (CTCL) for years. IFN-α is the most widely-used type for cutaneous lymphomas. IFN-α has been shown to be a highly active agent in CTCL with response rates ranging from 40% to 80%. In this review, the current information about PCLs and IFNs treatment is summarized.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001001 Cite this Article

REFERENCES

  1. Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 5: 177-180. Ref.: https://goo.gl/GOeMgn
  2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105: 3768-3785. Ref.: https://goo.gl/P3lMnA
  3. Khader A, Manakkad SP, Shaan M, Sarita Sasidharan Pillai, Najeeba Riyaz, et al. A Clinicopathological Analysis of Primary Cutaneous Lymphomas: A 6-year Observational Study at a Tertiary Care Center of South India. Indian J Dermatol. 2016; 61: 608-617. Ref.: https://goo.gl/Yl1QdG
  4. Cerroni L.. Past, present and future of cutaneous lymphomas. Semin Diagn Pathol. 2016; S0740-2570: 30091-30100. Ref.: https://goo.gl/8QyO76
  5. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007; 143: 854-859. Ref.: https://goo.gl/gPa2op
  6. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003; 139: 857-866. Ref.: https://goo.gl/2wkmIr
  7. Wain EM, Orchard GE, Whittaker SJ, Spittle MF, Russell-Jones R. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer. 2003; 98: 2282-2290. Ref.: https://goo.gl/PKHTQY
  8. Shohat M, Hodak E, Hannig H, Bodemer W, David M, et al. Evidence for the cofactor role of human T-cell lymphotropic virüs type 1in mycosis fungoides and Sezary syndrome. Br J Dermatol. 1999; 141: 44-49. Ref.: https://goo.gl/TIupYh
  9. Chong BF, Wilson AJ, Gibson HM, Hafner MS, Luo Y, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res. 2008; 14: 646-653. Ref.: https://goo.gl/YFxt5v
  10. Olsen E, Whittaker S, Kim Y, Duvic M, Prince HM, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphoma, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-2607. Ref.: https://goo.gl/w1IKQA
  11. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage based approach. J Natl Compr Canc Netw. 2008; 6: 436-442. Ref.: https://goo.gl/fW026Z
  12. Guarino MF, Olasolo J. Photodynamic Therapy for Mycosis Fungoides. Actas Dermosifiliogr. 2013; 104: 393-399. Ref.: https://goo.gl/dAldUU
  13. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol. 1990; 22: 381-401. Ref.: https://goo.gl/vWSrk3
  14. Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, et al. Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cüancer Society - Lymphoma Study Group. J Dermatol. 2013; 40: 2-14. Ref.: https://goo.gl/h09LQU
  15. Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma. 2003; 44: 611-618. Ref.: https://goo.gl/Mt66w7
  16. Takahashi K, Tanaka T, Fujita M, Horiguchi Y, Miyachi Y, et al. Cutaneous-type adult T-cell leukemia/lymphoma. A unique clinical feature with monoclonal T-cell proliferation detected by Southern blot analysis. Arch Dermatol. 1988; 124: 399-404. Ref.: https://goo.gl/09v8nG
  17. Camp B, Horwitz S, Pulitzer MP. Adult T-cell leukemia/lymphoma with follicular mucinosis: an unusual histopathological finding and a commentary. J Cutan Pathol. 2012; 39: 861-865. Ref.: https://goo.gl/3RQX66
  18. Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Clinical trials of adult T-cell leukaemia/lymphoma treatment. Leuk Res Treatment. 2012. Ref.: https://goo.gl/Rfn1es
  19. Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011; 117: 3961-3967. Ref.: https://goo.gl/RcWRWj
  20. Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol. 2005; 78: 232-239. Ref.: https://goo.gl/QYsTcW
  21. Oliveira PD, Farre L, Bittencourt AL. Adult T-cell leukemia/lymphoma. Rev Assoc Med Bras (1992). 2016; 62: 691-700. Ref.: https://goo.gl/PG4op5
  22. Whittaker SJ, Mackie RM. Cutaneous lymphoma and lymphocytic infiltrates. In: Burns. T, Breathnach S, Cox N, Griffith C, editors. Rook's textbook of dermatology. Italy: Blackwell Science Ltd; 2004; 54.1-54.53. Ref.: https://goo.gl/gDAOeL
  23. Biswas A, Gey van Pittius D, Stephens M, Smith AG. Reccurent primary cutaneous lymphoma with florid pseudoepitheliomatous hyperplasia masquerading as squamous cell carcinoma. Histopathology. 2008; 52: 755-758. Ref.: https://goo.gl/BIL8s1
  24. Singh S,  Gupta N,  Tekta GR. Imprint cytology facilitating the diagnosis of primary cutaneous anaplastic large cell lymphoma of iliac fossa. J Cytol. 2012; 29: 267-269. Ref.: https://goo.gl/wkHmZU
  25. Desai A, Telang GH, Olszewski AJ. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Ann Hematol. 2013; 92: 567-568. Ref.: https://goo.gl/3s6FqN
  26. Brice P, Cazals D, Mounier N, Verola O, Neidhart-Berard AM, et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Leukemia. 1998; 12: 213-219. Ref.: https://goo.gl/cDJl4L
  27. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118: 4024-4035. Ref.: https://goo.gl/e7SKZn
  28. Magorien J, Hillman JD, Pinter-Brown LC, Said J, Chiu MW. Acral lymphomatoid papulosis associated with poikilodermatous mycosis fungoides. Dermatol Online J. 2013; 19: 1. Ref.: https://goo.gl/z5rIFM
  29. Zackheim HS, Jones C, Leboit PE, Kashani-Sabet M, McCalmont TH, et al. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. J Am AcadDermatol. 2003; 49: 620-623. Ref.: https://goo.gl/zlqMbP
  30. Dasanu CA, Gopal S, Davis LK, Atienza JA. Letter to the editor: Subcutaneous panniculitis-like T-cell lymphoma in a patient with history of B-cell lymphoma treated successfully with chemotherapy 15 years prior. Journal of Oncology Pharmacy Practice. 2013; 3: 1-3. Ref.: https://goo.gl/IdB5oc
  31. Takada H, Ohga S, Mizuno Y, Suminoe A, Matsuzaki A, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br J Haematol. 1999; 106: 182-189. Ref.: https://goo.gl/7Rk3Sj
  32. Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008; 111: 838-845. Ref.: https://goo.gl/ISngr0
  33. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004; 101: 1404-1413. Ref.: https://goo.gl/t2Sy46
  34. Li YJ,  Li ZM,  Xia Y,  Huang JJ,  Huang HQ, et al. Serum C-Reactive Protein (CRP) as a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. PLoS One. 2013; 8: e64158. Ref.: https://goo.gl/oNQEPc
  35. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010; 21: 1032-1040. Ref.: https://goo.gl/iFQWVh
  36. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011; 22: 149-155. Ref.: https://goo.gl/Yq0ux8
  37. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012; 96: 617-623. Ref.: https://goo.gl/clLN5q
  38. Wang L, Wang Z, Chen X, Li Y, Wang K, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013; 119: 348-355. Ref.: https://goo.gl/tQsVFS
  39. Kempf W, Rozati S, Kerl K, French LE, Dummer R. Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomas. G Ital Dermatol Venereol. 2012; 147: 553-562. Ref.: https://goo.gl/PexpGi
  40. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut. 2011: 60; 1284-1293. Ref.: https://goo.gl/FW6H9N
  41. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer. 1986; 57: 1689-1695. Ref.: https://goo.gl/se87HG
  42. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995; 9: 1089-1107. Ref.: https://goo.gl/Vp8QuD
  43. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994; 121: 592-602. Ref.: https://goo.gl/U2pWkl
  44. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009; 27: 5418-5424. Ref.: https://goo.gl/MzQeY0
  45. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009; 27: 2916-2923. Ref.: https://goo.gl/kQoqiS
  46. Feldman DR, Kondagunta GV, Schwartz L, Patil S, Ishill N, et al. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma.Clin Genitourin Cancer. 2008; 6: 25-30. Ref.: https://goo.gl/6hQBVc
  47. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I ⁄ II study. J Clin Oncol. 2002; 20: 3841-3849. Ref.: https://goo.gl/L9gP7C
  48. Itoh Y, Okanoue T, Enjyo F, Morimoto M, Takeuchi T, et al. Elevated interleukin-6 and gamma-globulin during interferon therapy of hepatitis B. Am J Gastroenterol. 1992; 87: 1485-1487. Ref.: https://goo.gl/Vllfgy
  49. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995; 13: 2401-2407. Ref.: https://goo.gl/8qFG1E
  50. Bunn PA Jr, Foon KA, Ihde DC, Longo DL, Eddy J, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984; 101: 484-487. Ref.: https://goo.gl/xSpXeQ
  51. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993; 51: 63-72. Ref.: https://goo.gl/VjYKUv
  52. Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD. Complete remissions in- psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneousT-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol. 1993; 129: 747-752. Ref.: https://goo.gl/rpkuD8
  53. Rupoli S, Barulli S, Guiducci B, Offidani M, Mozzicafreddo G, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica. 1999; 84: 809-813. Ref.: https://goo.gl/1n56s0
  54. Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol. 2005; 75: 136-145. Ref.: https://goo.gl/G8VbPN
  55. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991; 24: 247-252. Ref.: https://goo.gl/9fG9LS
  56. Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A for patients with cutaneous T-cell lymphoma. Cancer. 2007; 109: 1799-1803. Ref.: https://goo.gl/8k77Zz
  57. Hüsken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, et al. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2012; 26: 71-78. Ref.: https://goo.gl/iyuuyK
  58. Zinzani PL, Mazza P, Gherlinzoni F. Beta interferon in the treatment of mycosis fungoides. Haematologica. 1988; 73: 547-548. Ref.: https://goo.gl/itFFrc
  59. Kaplan EH, Rosen ST, Norris DB, Roenigk HH Jr, Saks SR, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990; 82: 208-212. Ref.: https://goo.gl/35FjIl
  60. Jimbow K, Yamana K, Ishida O, Kawamura M, Ito Y, et al. Evaluation of rIFN-gamma in the treatment of lymphoma and melanoma of the skin by systemic and intralesional administration. Gan To Kagaku Ryoho. 1987; 14: 152-158. Ref.: https://goo.gl/Kaf9ab
  61. Cozzio A, Kempf W, Schmid-Meyer R, Gilliet M, Michaelis S, et al. Intra-lesional low-dose interferon alpha 2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma. 2006; 47: 865-869. Ref.: https://goo.gl/m9W0Pa
  62. Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997; 36: 311-314. Ref.: https://goo.gl/iDdZNW
  63. Parodi A, Micalizzi C, Rebora A. Intralesional natural interferon alpha in the treatment of Crosti's lymphoma (primary cutaneous B follicular centre-cell lymphoma): report of four cases. J Dermatol Treatment. 1996; 7: 105-107. Ref.: https://goo.gl/dBcl45
  64. Zenone T, Catimel G, Barbet N, Clavel M. Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a. Eur J Cancer. 1994; 30: 246-247. Ref.: https://goo.gl/NgPT4z